Increased peroxidation has been suggested as a pathological process in MS. (47) In agreement with that a decreased glutathione peroxidase activity and linoleic acid content in hematogenous cells from MS patients has been documented. (48-50) Supplementation with antioxidants (6.6 mg. of sodium selenite, 2 gm of vitamin C and 500 I.U. of vitamin E per day) increased and normalized within 3 weeks the glutathione peroxidase activity and the cellular content of linoleic acid. (51)
In an uncontrolled study patients showed a decrease of more than half the number of exacerbations when taking supplementation with calcium, magnesium and vitamin D. (52) Magnesium glutamate supplementation has been used for many years with great restorative effects in the treatment of MS patients by my father, Dr. Joseph Saine, in Montreal.
It is important that the MS patient avoid contact with toxic chemicals and fumes and choose an environment as free from pollution as possible. Many patients have reported the onset or exacerbation of symptoms after exposure to these agents.
Regarding the removal of mercury amalgams from the teeth, great care must be taken. Homeopaths have reported toxicity from these amalgams since their first use around 1840.53 H.C. Allen used to have his patients removed their amalgam fillings almost systematically. (54) In my experience, some MS patients have experienced great relief while others have suffered severe drawbacks from removing the amalgams. The sudden removal of these amalgams at the time the patient’s resistance is low can precipitate a severe exacerbation. I recommend the more vulnerable patients have their amalgams removed at a time of greater resistance by a competent dentist using all possible precautions to minimize trauma and further intoxication. Each dental session should be kept to less than 90 minutes and at only one tooth should be worked on to better evaluate the strain caused by the removal.
1. Stress reduction is crucial. This can achieved through inner changes and through changing of one’s lifestyle. Priorities should be established and goals should be set. The patient is encouraged to live a life which is more in harmony with their needs. Exercise including yoga, arts such as music, painting or dancing and meditation are encouraged.
2. Hydrotherapy in the hands of the trained physician is an ideal treatment to enhance the oxygenation and circulation of blood, to increase the oxidation and elimination of toxins, and to assist in the restoration of nervous equilibrium. Alternating applications to the spine and cold friction rubs would well complement constitutional treatment for both the acute and the chronic states of MS.
3. Electrotherapy has also proved to be very useful in stabilizing the MS patient. Bioccular transcerebral iontophoresis has shown remarkable results in most patients with MS in decreasing the accumulated scar tissue in the CNS and restoring normal nervous equilibrium. Ultra-violet and infra-red light can be applied daily especially during the winter months. The infra-red light seems more beneficial when applied to the palms of the hands and the soles of the feet 5-20 minutes daily.
4. Acupuncture has shown in non-control studies interesting results. (55-56) Further research is needed to better evaluate this ancient art in the treatment of the MS patient.
6â€”Management of acute infections
Acute respiratory tract infections such as sinusitis, colds and flus and acute urinary tract infections must be dealt with immediately with homeopathy and hygienic measures. These are critical times. If they are not attended soon enough the patient may experience a relapse of MS symptoms. Taking the remedy for the chronic state will often not prevent a relapse. If the acute condition is dissimilar to the chronic one and an acute remedy is prescribed the patient will recover quicker and this may prevent a relapse. In certain cases the chronic MS condition still relapses in spite of a quick recovery of the acute condition. The adoption of hygienic measures at such times may make the difference between a severe exacerbation and a good recovery. Rest is a must during a period of acute infection. Hydrotherapy applications will also be very useful in the hands of a knowledgeable physician.
Before and during the winter months the use of Influenzinum has been shown to be useful for preventing flu and Tuberculinum for preventing common colds. (58-59)Oscillococcinum has also been used successfully for preventing the flu. The prophylactic use of remedies must be individualized in each case depending on various factors such as the degree of exposure, sensitivity of the patient, past history of acute conditions, etc.
1. Herndon RM. Pathology and pathophysiology of multiple sclerosis. Semin Neurol 1985;5:99-106.
2. Morse PH. Retinal venous sheathing and neovascularization in disseminated sclerosis. Ann Ophthalmol 1975;7:949-52.
3. Vuia O. The bening form of multiple sclerosis: anatomo-clinical aspects. Acta Neurol Scand 1977;55:289-98.
4. Poser CM. Pathogenesis of multiple sclerosis. ActaNeuropathol 1986;71:1-10.
5. Ormerod IE, et al. Imaging of multiple sclerosis. In McDonald WI, Silberberg DH, eds. Multiple sclerosis. London: Butterworths, 1986:11-36.
6. Vandenbarrk AA. Critical immunologic events in multiple sclerosis: overview and summary. Res Monogr Immunol;7:257-70.
7. Larner AJ. Aetiological role of viruses in multiple sclerosis: a review. J R Soc Med 1986;79:412-7.
8. Govaerts A. HLA et la sclerose en plaques. Path Biol 1986;34:738-40.
9. Ebers GC. Immunogenetics and CSF studies in multiple sclerosis. Res Monogr Immunol 1984;7:233-56.
10. Francis DA, Batchelor JR, McDonald WI, et al. Multiple sclerosis in north-east Scotland. Brain 1987;110:181-96.
11. Martin JR. Herpes simplex virus types 1 and 2 and multiple sclerosis. Lancet;ii:777-81.
12. Warner HB, Carp RI. Multiple sclerosis and Epstein-Barr virus. Lancet;ii:1290.
13. Legac P. Le probleme histo-physio-pathologique de la sclerose en plaques. Bull Aca Sci 1960;250:2299-301.
14. Greisman SE, Wisseman GL. Studies of rickettsial toxins. J Immunol 1958;81:345-54.
15. Jadin Y. Maladies rickettsiennes en sclÃ©rose en plaques. Ann Soc Belge Med Trop 1962;42:321-45.
16. Field EJ, Chambers M. Rickettsial antibodies in multiple sclerosis. Br Med J 1970;1:30-32.
17. Legac P. Rickettsial antibodies in multiple sclerosis. Br Med J 1971; 2:341-2.
18. Szekeres J, Palffy GY, Paradi J. Rickettsia specific antibodies in multiple sclerosis. Lancet 1980;ii:1089-90.
19. Legac P, Wullfaert F, Arquie E, et al. RÃ©sultats de l’antiobiothÃ©rapie Ã large spectre sur 30 cas chroniques de sclÃ©rose en plaques rickettsienne et neo-rickettsienne. Bull Soc Path Exot 1964;57:263-76.
20. Warren S, Greenhill S, Warren KG. Emotional stress and the development of multiple sclerosis: Case control evidence of a relationship. J Chronic Dis 1982;35:821-31.
21. Bamford CR, Sibley WA, Thies C, et al. Trauma as an etiologic and aggravating factor in multiple sclerosis. Neurology 1981;31:1229-34.
22. Bamford CR, Sibley WA, Laguna JF. Anesthesia in multiple sclerosis. Can J Neurol Sci 1978:5:41-4.
23. McAlpine D, Compston N. Some aspects of the nature of disseminated sclerosis. Q J Med 1952;21:135-67.
24. Westlund KB, Kurland LT. Studies on multiple sclerosis in Winnipeg, Manitoba and New Orleans, Lousiana. Am J Hyg 1953;57:380-411.
25. Ingalls TH. Triggers for multiple sclerosis. Lancet 1986;ii:160.
26. Miller JH, Allison RS, Cheeseman EA, et al. Pregnancy as a factor influencing relapse in disseminated sclerosis. Brain1959;82:417-26.
27. Leibowitz U, Antonovsky A, Kats R, et al. Does pregnancy increase the risk of multiple sclerosis? J Neurol Neurosurg Psychiatry 1967;30:354-7.
28. Sibley Wa, Bamford Cr, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985;i;1313-5.
29. Gay D, Dick G, Upton G. Multiple sclerosis associated with sinusitis: case controlled study in general practice. Lancet;i:815-9.
30. Palffy G, Merei FT. The possible role of vaccines and sera in pathogenesis of multiple sclerosis. World Neurol 1961;2:167-71.
31. Miller H, Cendrowski W, Schapira K. Multiple sclerosis and vaccination. Br Med J 1967;2:210-3.
32. Smith CR, Scheinberg LC. Clinical features of multiple sclerosis. Semin Neurol 1985;5:85-93.
33. Sibley WA. Management of the patient with multiple sclerosis. Neurol 1985;5:134-45.
34. Krieger. Cas de guÃ©rison d’une paralysie progressive de la moelle Ã©piniÃ¨re. J du Dispensaire Hahnemann 1862-63;1:240-4.
35. Rorke WW. Results of homeopathic treatment in a well-defined and well-known chronic nervous disease. Br Hom J 1925;25:131-44.
36. Sloan TG. Dissiminated Sclerosis. Int Hah Ass Trans 1926;47:245-7.
37. Spalding RW. Relationship of Plumbum to multiple sclerosis. Hom Rec 1954-55;70:30-8.
38. Tyler ML. Little cases. Homoeopathy 1941;10:332.
39. Hahnemann S. Organon of Medicine. 6th ed, Los Angeles: JP Tarcher, Inc., 1982.
40. Russell WR. Multiple sclerosis: control of the disease. Oxford-New-York-Toronto: Pergamon Press, 1972.
41. Swank RL. Multiple sclerosis: twenty years on a low fat diet. Arch Neurol 1970;23:460-74.
42. Dworkin RH, Bates D, Millar JH, Paty DW. Linoleic acid and multiple sclerosis. A reanalysis of three double blind trials. Neurology 1984;34:1441-5.
43. Cendrowski W. Multiple sclerosis and MaxEPA. Br J Clin Pract 1986;40:365-7.
44. Sinclair HM. Forward. In Field EJ. Multiple sclerosis in childhood. Springfield: Charles C. Thomas, 1980:vii-xiii.
45. Field EJ, Joyce G. Simplified laboratory test for multiple sclerosis. Lancet 1976;ii:367.
46. Seaman GV, Swank RL, Zukoski CF. Red-cell-membrane differences in multiple sclerosis are acquired from plasma. Lancet 1979;i:1139.
47. Mickel H. Multiple sclerosis: A new hypothesis. Perspect Biol Med 1975:18:363-74.
48. Baker RW, Thompson RH, Zilke KJ. Fatty acid composition of brain lecithins in multiple sclerosis. Lancet 1963;i:26.
49. Jensen GE, Gissel-Nielson G, Clausen J. Leukocyte peroxidase activity and selenium level in multiple sclerosis. J Neurol Sci 1980;48:61-7.
50. Mazzella GL, Sinforiani E, Salvodi F, et al. Blood cells glutathione peroxidase activity and selenium in multiple sclerosis. Eur Neurol 1983;22:442-6.
51. Jensen GE, Clausen J. Glutathione peroxidase activity, associated enzymes and substrates in blood cells from patients with multiple sclerosis-Effects of antioxidant supplementation. Acta Pharmacol Toxicol(Suppl) 1986;VII:450-3.
52. Golberg P, Fleming MC, Picard EH. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hyp 1986;21:193-200.
53. E.C. (An anonymous homeopathic physician). Poisoning vermilion in dental plates. New Engl Med Gaz 1872;7:69-74.
54. Allen HC. A case of mercurial deafness. Trans Hom Med Soc Penn 1906;43:217-20.
55. Smith MO, Rabinovitz N. Acupuncture treatment of multiple: two detailed clinical presentations. Lincoln Acupuncture Clinic of Lincoln Hospital, New-York, 1987.
56. Steinberger A. Specific irritability of acupuncture points as an early symptom of multiple sclerosis. Am J Chin Med 1986;14:175-8.
57. Schmidt P. Defective illnesses. Calcuta: Hahnemann Pub. Co., 1980.
58. Krishnamurty PS. Report on the use of Influenzinum during the outbreak of epidemic in India in 1968. Hahn Glean 1970;37:225-6.
59. Eizayaga FX. Valor de Influenzinum como preventivo de la gripe. Homeopatia 1973;40:21-2.
Dr Andre Saine
Dean of the Canadian Academy of Homeopathy Dr. AndrÃ© Saine is a graduate of National College of Naturopathic Medicine in Portland, Oregon and has been the Dean of the Canadian Academy of Homeopathy since 1986. He has taught homeopathy extensively in North America and Europe for over 25 years to health care professionals.